IGF-1 DES
A truncated version of insulin-like growth factor 1 (missing the first three amino acids) that binds IGF-binding proteins poorly, making it very potent locally but short-acting. It is a research / performance compound — not an approved drug — and is banned in sport.
Quick take
- What it is: a shortened form of IGF-1 missing its first three amino acids, which makes it very potent but short-lived.
- What people use it for: localised muscle growth and recovery, based on its strong, fast IGF-1 activity.
- What we actually know: it is highly active in cell culture; there is essentially no controlled human data, and it carries real metabolic risks.
- Status: a research / performance compound, not FDA-approved, and prohibited in sport.
What it is
IGF-1 DES, fully DES(1-3) IGF-1, is a truncated analogue of insulin-like growth factor 1 (IGF-1) that is missing the first three amino acids of the natural molecule. That small deletion sharply reduces its affinity for the IGF-binding proteins that normally control IGF-1, which makes it more potent than native IGF-1 — but also short-acting.1
Like IGF-1 LR3, it originated as a research reagent. Its use as a “performance” compound is an off-label, unapproved extension.
How it works
IGF-1 is a powerful anabolic signal driving cell growth, protein synthesis and repair.1,2 Because IGF-1 DES largely escapes binding-protein control, free active peptide is immediately available, producing a strong but brief IGF-1 signal. This is the basis for claims of a more localised, immediate effect compared with the longer-acting LR3 variant — though that distinction is mostly theoretical in humans.
What the evidence shows
Cell & animal studies
DES(1-3) IGF-1 is well documented as a potent growth driver in cell culture and in animal work, reflecting its enhanced potency over native IGF-1.2
Human studies
Controlled human trials of IGF-1 DES for muscle growth or recovery are essentially absent. The performance claims rest on IGF-1 biology and anecdote, not on demonstrated, safe benefit in people.3 Its potency makes the lack of human safety data particularly relevant.
Dosages reported in the literature
Informational only. The figures below describe doses reported informally rather than in controlled human trials. They are not a recommendation or a prescription, and appropriate use, if any, should be determined by a qualified healthcare professional who can account for your individual situation.
| Setting | Route | Reported range |
|---|---|---|
| Cell / animal research | Various | Not directly applicable to humans |
| Anecdotal (performance) | Subcutaneous / intramuscular | Reported in microgram amounts; protocols vary widely |
Because there are no dose-finding human trials for these uses, no range here should be read as established as safe or effective.
Safety & side effects
As with other potent IGF-1 compounds, the most concrete risk is hypoglycaemia (low blood sugar), owing to overlap with insulin signalling.3 Sustained or repeated stimulation of a powerful growth pathway also raises theoretical concerns about abnormal tissue growth, a recognised caution for IGF-1-type compounds absent controlled human safety data. There is essentially no long-term human safety information.
As with all peptides from the unregulated market, product purity, identity and dose accuracy vary between sources.
Legal & regulatory status
IGF-1 DES is not approved by the FDA for any use and is best described as a research reagent and unapproved performance compound. IGF-1 and its analogues are prohibited in sport at all times by the World Anti-Doping Agency (category S2, peptide hormones, growth factors and related substances).4 Rules vary by country and change over time.
References
- Ross M, Francis GL, Szabo L, Wallace JC, Ballard FJ. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J. 1989;258(1):267-272. [PMID 2539101, doi:10.1042/bj2580267]
- Barclay RD, Burd NA, Tyler C, Tillin NA, Mackenzie RW. The Role of the IGF-1 Signaling Cascade in Muscle Protein Synthesis and Anabolic Resistance in Aging Skeletal Muscle. Front Nutr. 2019;6:146. [PMID 31552262, doi:10.3389/fnut.2019.00146]
- Anderson LJ, Tamayose JM, Garcia JM. Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects. Mol Cell Endocrinol. 2018;464:65-74. [PMID 28606865, doi:10.1016/j.mce.2017.06.010]
- World Anti-Doping Agency. The Prohibited List - S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics (IGF-1 / mecasermin and its analogues prohibited at all times). World Anti-Doping Agency. [wada-ama.org]